Navigation Links
Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz
Date:8/23/2014

Albany, NewYork (PRWEB) August 23, 2014

GBI Research, the leading business intelligence provider, has released its latest research: “Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market”, which provides in-depth analysis of the critical care market in the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecasts to 2020. It covers critical care indications that are being treated using the five major plasma-derived products of albumin, anti-thrombin concentrates, factor XIII concentrates, fibrinogen concentrates, and prothrombin complex concentrates.

Full Report With TOC @ http://www.researchmoz.us/critical-care-therapeutics-in-major-developed-markets-to-2020-new-and-late-stage-four-factor-pccs-and-recombinant-products-to-drive-market-report.html

The total value of the critical care market in the major developed markets was estimated at $1.8 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.7% to $2.5 billion in 2019. This growth is attributed to the recent approval of new factor concentrates in the US that are expected to witness increasing uptake in the forecast period. Factor concentrates are increasingly preferred due to their lower infection risks over older alternatives such as FFP and cryoprecipitate in critical care settings. The US accounts for the largest share (41%) of the global critical care market and is expected to post high growth at a CAGR of 7.5% until 2020. KCentra, the first four-factor PCC in the US, and Tretten, the first recombinant FXIII concentrate, were approved in 2013 and are expected to witness good uptake in the forecast period. Two additional factor concentrates approved in the US in 2009 – RiaStap (human fibrinogen concentrate) and ATryn (recombinant AT concentrate) – are also expected to increase their uptake, which will contribute to market growth. With no new significant launches in the forecast period, the European market is estimated to witness much slower growth, with the UK at a CAGR of 3.0%, France at 2.5%, Germany and Spain both at 2.3%, and Italy at 2.0%

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in critical care in the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada.

The report includes:

  • A brief introduction to the five major plasma-derived products in critical care and the indications that they are being used to treat, as well as disease overview, epidemiology, other treatment options, and treatment patterns
  • Analysis of major marketed products in critical care, covering product performance in terms of the safety and efficacy of recent approvals
  • A review of the critical care pipeline, including individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period
  • Multi-scenario forecasts of the critical care market over the 2013–2020 period in the eight major developed markets
  • Key drivers and restraints that have had and are expected to have a significant impact on the market
  • An overview of major licensing and co-development agreements that could affect growth trends

All Latest Market Research Report @ http://www.researchmoz.us/latest-report.html

Reasons to Buy

  • The report will enhance your decision-making capability by allowing you to:
  • Align your product portfolio to markets with high growth potential
  • Develop market entry and expansion strategies by identifying the regions and therapeutic segments poised for strong growth
  • Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the critical care drugs market
  • Develop key strategic initiatives based on an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

For More Information Kindly Contact:
Email: sales(at)researchmoz(dot)us   
Blog: http://industryresearchnews.blogspot.com

Read the full story at http://www.prweb.com/releases/2014/08/prweb12114682.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Primary care physicians can be critical resource for abused women in rural areas
2. CHEST releases new expert guidance in care of the critically ill and injured
3. Download HeartBeat Experts White Paper: A Stakeholder Engagement Strategy is Critical for the Evolving Melanoma Treatment Setting
4. Proteins critical to wound healing identified
5. United Nations Foundation Mobilizes Critical Support for the Millennium Development Goals
6. Central Ohio Trauma System (COTS) Relies on Onset Technology's OnPage® Critical Messaging Alerts System When Disaster Strikes
7. European Super Critical Fluid Chromatography Reagents Market is Expected to Reach $75.5 million in 2018 - New Report by MicroMarket Monitor
8. North America Super Critical Fluid Chromatography (Reagents) Market is Expected to Reach $107.8 Million in 2018 - New Report by MicroMarket Monitor
9. How critically ill infants can benefit most from human milk
10. Pyruvate oxidation is critical determinant of pancreatic islet number and β-cell mass
11. The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... will spark a conversation on the current obstacles facing infection prevention and offer ... preventable deaths caused by these infections. , The print component of “Fighting ...
(Date:3/24/2017)... ... March 24, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is pleased ... Huebner Road. The clinic is the group’s 7th location in San Antonio and 23rd ... PT, will provide care from the clinic, which opened March 22, 2017. ...
(Date:3/24/2017)... ... 2017 , ... As the standards bearer of advanced cancer ... positions them as the go-to thought leader in all matters concerning oncology nursing. ... always-on, always-fresh news, views and advocacy engine, called ONS Voice. , The ONS ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is to ... Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. Food ...
(Date:3/24/2017)... ... 2017 , ... “Vintage and Harvest A Cultivation of Christian Love” is the ... in North Carolina with his wife, Anna Marie. He and his wife are the ... is also the author of “Shadow and Substance.” , “Love, the agape kind, is ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017  Zymo Research Corp., also known ... Inc., who designs, manufactures and distributes liquid ... teams Zymo Research,s DNA methylation detection and ... products with Hamilton,s high-throughput automation platforms. Zymo ... microbiomics and RNA isolation for use on ...
(Date:3/24/2017)... , March 24, 2017   The ... organization within medical affairs in the pharmaceutical industry ... the chair of a newly formed scientific advisory ... members to form the first ever medical affairs ... For more information about the ACMA, please visit  ...
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research and ... (IPF) Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with ... Corporation, Merck & Co., Inc., Biogen and Sanofi are involved in the ... candidates, of which one is in Phase III stage, 15 are in ...
Breaking Medicine Technology: